ResMed Inc. (RMD)

ResMed's stock has been influenced by several events in the past six months. The company announced its Q1 and Q2 fiscal year 2026 earnings, held its annual stockholders meeting, and expanded its U.S. operations with a new distribution center. ResMed's Global Sleep Survey highlighted sleep as a top health priority. The stock underperformed against the S&P 500, and the potential threat from weight-loss drugs was identified as a growing risk. There were insider selling and analyst adjustments, and the stock experienced a recent decline. ResMed is scheduled to report its Third Quarter Fiscal 2026 Earnings on April 30, 2026.

The demand for ResMed's products and services is primarily driven by structural market trends rather than distinct seasonality. These trends include the increasing diagnosis of sleep apnea, aging global populations, and the rising prevalence of obesity. The company also engages in targeted campaigns, such as holiday-related promotions, to drive demand and brand awareness. The shift towards home-based care and the adoption of digital health solutions also contribute to sustained demand.

ResMed, Inc. is a global medical equipment company specializing in cloud-connectable medical devices and software solutions for sleep apnea, COPD, and other respiratory conditions. Their products include flow generators, masks, CPAP and APAP machines, bilevel devices, ventilators, and digital health technologies. ResMed also provides out-of-hospital care software platforms and emphasizes digital health and AI-powered solutions.

ResMed operates in over 140 countries with a global team of over 10,000 employees. Approximately two-thirds of its revenue is generated in the Americas, with Europe, Japan, and Australia also representing significant markets. The company has manufacturing facilities in Australia, Singapore, France, and the United States.

ResMed maintains a strong brand reputation, evidenced by various accolades and recognitions. These include a Red Dot Design Award for AirTouch N30i in 2025, recognition as one of America's "Management Top 250" companies by The Wall Street Journal from 2019-2024, and being named one of "America's Most Responsible Companies" by Newsweek/Statista from 2020-2024. ResMed was also ranked for Best Customer Service and America's Best Midsize Employers by Forbes in 2026, and listed among America's Most Trusted Companies and America's Best Companies by Forbes in 2025.

ResMed Inc. is largely favored by institutional owners, who collectively hold a significant portion of the company. As of December 2025, institutional investors held 66.4% of outstanding stock. Major institutional shareholders include The Vanguard Group, Inc., BlackRock, Inc., and State Street Corp, among others.